IVYSPRING INTERNATIONAL PUBLISHER

Theranostics

2020; 10(16): 7406-7408. doi: 10.7150/thno.48039

Erratum

Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression: Erratum

Maria Tsioumpekou[1,2,3*], Sara I. Cunha[3,4*], Haisha Ma[3,5], Aive Åhgren[3], Jessica Cedervall[1], Anna-Karin Olsson[1], Carl-Henrik Heldin[1,3] and Johan Lennartsson[2,3]✉

1. Department of Medical Biochemistry and Microbiology, Uppsala University, Sweden.
2. Department of Pharmaceutical Biosciences, Uppsala University, Sweden.
3. Ludwig Institute for Cancer Research, Uppsala Branch, Uppsala University, Sweden.
4. Department of Immunology, Genetics and Pathology, Uppsala University, Sweden.
5. Department of Neuroscience, Uppsala University, Sweden.

* These authors contributed equally to the study.

✉ Corresponding author: johan.lennartsson@farmbio.uu.se

Published: 2020.06.11

Corrected article: *Theranostics* 2020; 10(3):1122-1135. doi:10.7150/thno.37851.

We noticed an error in figure 5 in our published manuscript [1]. In figure 5 one of the axis in the quantification has been labelled with the wrong marker. Below is a correct version of figure 5.



Figure 5. Selective inhibition of PDGFRβ differentially affects tumor pericyte populations in LLC and B16/PDGF-BB tumors. LLC (**A**, **C**, **E**) and B16/PDGF-BB (**B**, **D**, **F**) tumors were grown in ASKA PDGFRβ mutant mice after treatment with vehicle, 1-NaPP1 or imatinib for 10 consecutive days; sections from tumors were co-immunostained for CD31/podocalyxin and PDGFRβ. PDGFRβ+ pericyte coverage was quantified in LLC (**A**; CD31, green; PDGFRβ, red) and B16/PDGF-BB (**B**; podocalyxin, red; PDGFRβ, green). CD31 and α-SMA were co-immunostained and α-SMA+ pericyte coverage quantified in LLC (**C**) and B16/PDGF-BB (**D**) tumors (CD31, green; α-SMA, red). Podocalyxin or CD31 and NG2 were co-immunostained and NG2+ pericyte coverage quantified in LLC (**E**) and B16/PDGF-BB (**F**) tumors (LLC: CD31, green; NG2, red; B16/PDGF-BB: podocalyxin, red; NG2, green). >20 field 200x magnification images were scored for each mouse (n=5 or more animals). Scale bar, 50 μm. *p<0.05, **p<0.01 and ***p<0.001.

References

[1] Tsioumpekou M, Cunha SI, Ma H, Åhgren A, Cedervall J, Olsson AK, Heldin CH, Lennartsson J. Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression. Theranostics 2020; 10(3):1122-1135. doi:10.7150/thno.37851.